An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma

Trial Profile

An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs CCX 872 (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 17 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
    • 17 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Nov 2017.
    • 02 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top